Personalized therapy on the horizon for squamous cell carcinoma of the lung

Lung Cancer

Volumn 80, Issue 3, 2013, Pages 249-255

  Kim, Han Sang ^a   Mitsudomi, Tetsuya ^b   Soo, Ross A ^c   Cho, Byoung Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

^b KINKI UNIVERSITY   (Japan)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Biomarker; Driver mutation; Non small cell lung cancer; Squamous cell carcinoma; Targeted therapy

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; CETUXIMAB; CISPLATIN; CRENOLANIB; CYCLIN DEPENDENT KINASE 6; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GEFITINIB; GEMCITABINE; HLA A ANTIGEN; IPILIMUMAB; MESSENGER RNA; NAVELBINE; NECITUMUMAB; NOTCH1 RECEPTOR; ONARTUZUMAB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN P53; PROTEIN P63; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR SOX2; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; LUNG SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION;

EID: 84877156527     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.02.015     Document Type: Review

References (77)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Sandler A.B., Johnson D.H., Herbst R.S. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 2004, 10:4258s-4262s.
3. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2005, 23:3235-3242.
4. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
5. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
6. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
7. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
8. Meyerson M., Gabriel S., Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010, 11:685-696.
9. Campbell P.J., Stephens P.J., Pleasance E.D., O'Meara S., Li H., Santarius T., et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 2008, 40:722-729.
10. Pleasance E.D., Stephens P.J., O'Meara S., McBride D.J., Meynert A., Jones D., et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463:184-190.
11. Lee W., Jiang Z., Liu J., Haverty P.M., Guan Y., Stinson J., et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010, 465:473-477.
12. The Cancer Genome Atlas Research N, Genome sequencing centres: Broad I, Hammerman P.S., Lawrence M.S., Voet D., Jing R., et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
13. Imielinski M., Berger A.H., Hammerman P.S., Hernandez B., Pugh T.J., Hodis E., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012, 150:1107-1120.
14. Govindan R., Ding L., Griffith M., Subramanian J., Dees N.D., Kanchi K.L., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012, 150:1121-1134.
15. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450:893-898.
16. Paul Paik A.H., Lu Wang, Natasha Rekhtman, Marc Ladanyi, Kris Mark G. Multiplex testing for driver mutations in squamous cell carcinomas of the lung. J Clin Oncol 2012, 30. (suppl; abstr 7505).
17. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006, 7:1041-1053.
18. Socinski M.A., Bondarenko I., Karaseva N.A., Makhson A.M., Vynnychenko I., Okamoto I., et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012, 30:2055-2062.
19. Yoo S.H., Park Y.S., Kim H.R., Sung S.W., Kim J.H., Shim Y.S., et al. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 2003, 42:195-202.
20. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
21. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
22. Rekhtman N., Paik P.K., Arcila M.E., Tafe L.J., Oxnard G.R., Moreira A.L., et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012, 18:1167-1176.
23. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
24. Pirker R., Pereira J.R., von Pawel J., Krzakowski M., Ramlau R., Park K., et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012, 13:33-42.
25. Masuya D., Huang C., Liu D., Nakashima T., Kameyama K., Haba R., et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 2004, 90:1555-1562.
26. Go H., Jeon Y.K., Park H.J., Sung S.W., Seo J.W., Chung D.H. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 2010, 5:305-313.
27. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
28. Tanizaki J., Okamoto I., Sakai K., Nakagawa K. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer 2011, 105:807-813.
29. Spigel D.R.T.J.E., Ramlau R., Daniel D.B., Goldschmidt J.H., Blumenschein G.R., Krzakowski M.J., et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011, 29. (suppl; abstr 7505).
30. Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4:505-518.
31. Dziadziuszko R., Merrick D.T., Witta S.E., Mendoza A.D., Szostakiewicz B., Szymanowska A., et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 2010, 28:2174-2180.
32. Karp D.D., Paz-Ares L.G., Novello S., Haluska P., Garland L., Cardenal F., et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009, 27:2516-2522.
33. Jassem J.C.J.L., Karp D.D., Mok T., Benner R.J., Green S.J., Park K., et al. Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28:15s. (suppl; abstr 7500) 2010.
34. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater?. J Natl Cancer Inst 2012, 104:975-981.
35. Krishnakumar R., Kraus W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010, 39:8-24.
36. Ossovskaya V., Koo I.C., Kaldjian E.P., Alvares C., Sherman B.M. Upregulation of poly (ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 2010, 1:812-821.
37. Davar D., Beumer J.H., Hamieh L., Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 2012, 19:3907-3921.
38. Spigel D.R.P.G.H., Hainsworth J.D., De Marinis F., Kabbinavar F.F., Kim E.S., Lynch T.J., et al. Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN. Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 29. (suppl; abstr TPS220).
39. Petersen R.P., Campa M.J., Sperlazza J., Conlon D., Joshi M.B., Harpole D.H., et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006, 107:2866-2872.
40. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012, 30:2046-2054.
41. Suzanne Louise Topalian J.R.B., Stephen Hodi F., David F.McDermott, David C.Smith, Scott N.Gettinger, Janis M.Taube, et al. Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. 2012 ASCO Annual Meeting. J Clin Oncol 2012, 30. (suppl; abstr CRA2509).
42. Hiraoka K., Miyamoto M., Cho Y., Suzuoki M., Oshikiri T., Nakakubo Y., et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006, 94:275-280.
43. Boland J.M., Kwon E.D., Harrington S.M., Wampfler J.A., Tang H., Yang P., et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer 2012, 14:157-163.
44. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
45. Strong J.E., Coffey M.C., Tang D., Sabinin P., Lee P.W. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998, 17:3351-3362.
46. Joensuu H., Anttonen A., Eriksson M., Makitaro R., Alfthan H., Kinnula V., et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 2002, 62:5210-5217.
47. Fischer H., Taylor N., Allerstorfer S., Grusch M., Sonvilla G., Holzmann K., et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 2008, 7:3408-3419.
48. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10:116-129.
49. Weiss J., Sos M.L., Seidel D., Peifer M., Zander T., Heuckmann J.M., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010, 2. 62ra93.
50. Hye Ryun Kim D.J.K., Dae Ryong Kang, Jin Gu Lee, Sun Min Lim, Chang Young Lee, Sun Young Rha, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in resected squamous cell lung cancer patients. J Clin Oncol 2012, 31:731-737.
51. Heist R.S., Mino-Kenudson M., Sequist L.V., Tammireddy S., Morrissey L., Christiani D.C., et al. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 2012, 7:1775-1780.
52. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009, 8:627-644.
53. Kawano O., Sasaki H., Endo K., Suzuki E., Haneda H., Yukiue H., et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006, 54:209-215.
54. Okudela K., Suzuki M., Kageyama S., Bunai T., Nagura K., Igarashi H., et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int 2007, 57:664-671.
55. Yamamoto H., Shigematsu H., Nomura M., Lockwood W.W., Sato M., Okumura N., et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008, 68:6913-6921.
56. Janku F., Tsimberidou A.M., Garrido-Laguna I., Wang X., Luthra R., Hong D.S., et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011, 10:558-565.
57. Marsit C.J., Zheng S., Aldape K., Hinds P.W., Nelson H.H., Wiencke J.K., et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005, 36:768-776.
58. Jin G., Kim M.J., Jeon H.S., Choi J.E., Kim D.S., Lee E.B., et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 2010, 69:279-283.
59. Sos M.L., Koker M., Weir B.A., Heynck S., Rabinovsky R., Zander T., et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009, 69:3256-3261.
60. Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S.H., et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454:776-779.
61. Wee S., Wiederschain D., Maira S.M., Loo A., Miller C., deBeaumont R., et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci USA 2008, 105:13057-13062.
62. Zhang H., Bajraszewski N., Wu E., Wang H., Moseman A.P., Dabora S.L., et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007, 117:730-738.
63. Williams L.T. Signal transduction by the platelet-derived growth factor receptor. Science 1989, 243:1564-1570.
64. Ramos A.H., Dutt A., Mermel C., Perner S., Cho J., Lafargue C.J., et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 2009, 8:2042-2050.
65. Scagliotti G., Novello S., von Pawel J., Reck M., Pereira J.R., Thomas M., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:1835-1842.
66. Day E., Waters B., Spiegel K., Alnadaf T., Manley P.W., Buchdunger E., et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 2008, 599:44-53.
67. Hammerman P.S., Sos M.L., Ramos A.H., Xu C., Dutt A., Zhou W., et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011, 1:78-89.
68. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
69. Paik P.K., Arcila M.E., Fara M., Sima C.S., Miller V.A., Kris M.G., et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011, 29:2046-2051.
70. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
71. Grob T.J., Kannengiesser I., Tsourlakis M.C., Atanackovic D., Koenig A.M., Vashist Y.K., et al. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod Pathol 2012, 25:1566-1573.
72. Kishimoto Y., Murakami Y., Shiraishi M., Hayashi K., Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 1992, 52:4799-4804.
73. Yamaguchi K., Wu L., Caballero O.L., Hibi K., Trink B., Resto V., et al. Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. Int J Cancer 2000, 86:684-689.
74. Hibi K., Trink B., Patturajan M., Westra W.H., Caballero O.L., Hill D.E., et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000, 97:5462-5467.
75. Ji H., Zhao X., Yuza Y., Shimamura T., Li D., Protopopov A., et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 2006, 103:7817-7822.
76. Shibata T., Ohta T., Tong K.I., Kokubu A., Odogawa R., Tsuta K., et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 2008, 105:13568-13573.
77. Bass A.J., Watanabe H., Mermel C.H., Yu S., Perner S., Verhaak R.G., et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009, 41:1238-1242.